Q BioMed Inc. – OTC:QBIO

Add to watchlist

Market closed

Open in about 7 hours

-100.00%

month

-100.00%

quarter

-100.00%

year

Market Cap	351.59K
Enterprise value	4.26M

P/E	-0.06
EV/Sales	11.31
EV/EBITDA	-0.85
Price/Sales	1.66
Price/Book	-0.08
PEG ratio	N/A
EPS	N/A

Revenue	N/A
EBITDA	N/A
Income	N/A
Revenue Q/Q	-100%
Revenue Y/Y	-96.00%

Profit margin	-1705.28%
Oper. margin	-1195.07%
Gross margin	20.58%
EBIT margin	-1195.07%
EBITDA margin	N/A

Get more financial ratios!

Every financial ratio you might need
10 years history
Forward ratios (Analysts estimates)

Personalize your watchlist with companies you want to keep track of and get notified in the smart feed every time fresh news arrives.

Q BioMed Inc. (OTC:QBIO): Profit margin
Nov 2022	12.53K	2.30M	18368.34%
Feb 2023	2.5K	-826.41K	-33056.44%
May 2023	0	0
Aug 2023	0	0

Q BioMed Inc. (OTC:QBIO): Payout ratio
Payout ratio	0%

Q BioMed Inc. (OTC:QBIO): Dividend Yield
2018
2019
2020	1.54%
2021	4.13%
2022

Q BioMed Inc. (OTC:QBIO): Debt to assets
Nov 2022	3515517	8.13M	231.34%
Feb 2023	3464682	9.90M	285.91%
May 2023	0	0
Aug 2023	0	0

Q BioMed Inc. (OTC:QBIO): Cash Flow
Nov 2022	2.66M	-3.14M	387.73K
Feb 2023	-138.18K	0	111.38K
May 2023	0	0	0
Aug 2023	0	0	0

Q BioMed alternative data

Q BioMed Inc. (OTC:QBIO): Employee count
Aug 2023	3
Sep 2023	3
Oct 2023	3
Nov 2023	3
Dec 2023	3
Jan 2024	3
Feb 2024	3
Mar 2024	3
Apr 2024	3
May 2024	3
Jun 2024	3
Jul 2024	3

Q BioMed Inc. (OTC:QBIO): Insider trades (number of shares)
Period	Buy	Sel
May 2018	150000	0
Jun 2018	0	26500
Jul 2018	0	38100

Transaction	Date	Insider	Security	Shares	Price per share	Total value
Sale	12 Jul 2018	CORIN DENIS director, 10 percent owner, officer: Chief Exe.. director, 10 percent owner, off..	Common Stock	6,400	N/A	N/A
Sale	10 Jul 2018	CORIN DENIS director, 10 percent owner, officer: Chief Exe.. director, 10 percent owner, off..	Common Stock	7,000	$2.85	$19,936
Sale	9 Jul 2018	CORIN DENIS director, 10 percent owner, officer: Chief Exe.. director, 10 percent owner, off..	Common Stock	7,000	$2.85	$19,936
Sale	6 Jul 2018	CORIN DENIS director, 10 percent owner, officer: Chief Exe.. director, 10 percent owner, off..	Common Stock	6,900	$3.58	$24,688
Sale	5 Jul 2018	CORIN DENIS director, 10 percent owner, officer: Chief Exe.. director, 10 percent owner, off..	Common Stock	6,600	$3.54	$23,344
Sale	3 Jul 2018	CORIN DENIS director, 10 percent owner, officer: Chief Exe.. director, 10 percent owner, off..	Common Stock	2,200	$3.46	$7,610
Sale	2 Jul 2018	CORIN DENIS director, 10 percent owner, officer: Chief Exe.. director, 10 percent owner, off..	Common Stock	2,000	$3.42	$6,836
Sale	29 Jun 2018	CORIN DENIS director, 10 percent owner, officer: Chief Exe.. director, 10 percent owner, off..	Common Stock	2,100	$3.4	$7,138
Sale	28 Jun 2018	CORIN DENIS director, 10 percent owner, officer: Chief Exe.. director, 10 percent owner, off..	Common Stock	5,300	$3.39	$17,962
Sale	27 Jun 2018	CORIN DENIS director, 10 percent owner, officer: Chief Exe.. director, 10 percent owner, off..	Common Stock	4,900	$3.44	$16,832

Q BioMed
Executives

Insider	Age	Compensation
Mr. William S. Rosenstadt (1968) Chief Legal Officer, Gen. Counsel & Director	57	$300,000
Mr. Denis D. Corin (1973) Chairman, Chief Executive Officer, Chief Financial Officer, Pres and Acting Principal Financial & Accounting Officer	52	$295,000
Ms. Kristin Marvin Keller (1976) Chief Commercial Officer	49	$212,400

Q BioMed
Latest News

Friday, 14 April 2023
09:05	Q BioMed receives US patent and notice of allowance in Europe for Uttroside B; seeks ways to boost shareholder value	Proactive Investors
Friday, 10 February 2023
09:21	Q BioMed gets notice of allowable US patent for liver cancer treatment Uttroside B	Proactive Investors
Monday, 14 November 2022
11:09	Q BioMed boosted by multi-million dollar asset as it converts long-term royalty into equity stake in Mannin Research	Proactive Investors
Tuesday, 27 September 2022
09:46	Q Biomed announces patent for groundbreaking GDF15 biomarker for glaucoma detection and treatment	Proactive Investors
Friday, 29 July 2022
10:43	Q BioMed reports Strontium89 sales revenue surge in shareholder update	Proactive Investors
Tuesday, 26 July 2022
10:10	Q BioMed says new publication shows superior safety and efficacy of Uttroside-B versus FDA approved drug Sorafenib	Proactive Investors
Friday, 6 May 2022
10:41	Q BioMed says its strategy is paying off as it outlines its value proposition in multibillion-dollar markets	Proactive Investors
Wednesday, 16 March 2022
09:44	Q BioMed announces publication of research supporting efficacy and development of its Uttroside-B chemotherapeutic to treat liver cancer	Proactive Investors
Monday, 14 February 2022
13:21	Q BioMed outlines strategic direction and goals for 2022	Proactive Investors

Frequently Asked Questions (FAQ)

What's the price of Q BioMed stock today?

One share of Q BioMed stock can currently be purchased for approximately $0.
When is Q BioMed's next earnings date?

Unfortunately, Q BioMed's (QBIO) next earnings date is currently unknown.
Does Q BioMed pay dividends?

No, Q BioMed does not pay dividends.
How much money does Q BioMed make?

Q BioMed has a market capitalization of 351.59K and it's past years’ income statements indicate that its last revenue has increased compared to the previous period by 45.38% to 284.35K US dollars.
What is Q BioMed's stock symbol?

Q BioMed Inc. is traded on the OTC under the ticker symbol "QBIO".
What is Q BioMed's primary industry?

Company operates in the Healthcare sector and Biotechnology industry.
How do i buy shares of Q BioMed?

Shares of Q BioMed can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Who are Q BioMed's key executives?
Q BioMed's management team includes the following people:
- Mr. William S. Rosenstadt Chief Legal Officer, Gen. Counsel & Director(age: 57, pay: $300,000)
- Mr. Denis D. Corin Chairman, Chief Executive Officer, Chief Financial Officer, Pres and Acting Principal Financial & Accounting Officer(age: 52, pay: $295,000)
- Ms. Kristin Marvin Keller Chief Commercial Officer(age: 49, pay: $212,400)
How many employees does Q BioMed have?

As Jul 2024, Q BioMed employs 3 workers.
When Q BioMed went public?

Q BioMed Inc. is publicly traded company for more then 10 years since IPO on 17 Jun 2015.
What is Q BioMed's official website?

The official website for Q BioMed is qbiomed.com.
Where are Q BioMed's headquarters?

Q BioMed is headquartered at 366 Madison Avenue, New York, NY.
How can i contact Q BioMed?

Q BioMed's mailing address is 366 Madison Avenue, New York, NY and company can be reached via phone at +212 5880022.

Q BioMed Inc.

qbiomed.com

Exchange:

OTC

Full time employees:

Industry:

Biotechnology

Sector:

Healthcare

Q BioMed Inc., a biomedical acceleration and development company, focuses on licensing, acquiring, and providing resources to life sciences and healthcare companies. The company offers Strontium Chloride SR89 and Metastron, a radiopharmaceutical therapeutic for the treatment of metastatic bone cancer pain. It is also developing Man-01, a pre-clinical lead candidate for the treatment of primary open angle glaucoma; QBM-001 for rare pediatric non-verbal autism spectrum disorder; and Uttroside-B for liver cancer. Q BioMed Inc. has a partnership with Mannin Research Inc. for the development of therapeutics to treat acute respiratory distress syndrome, glaucoma, kidney diseases, and others. The company was formerly known as ISMO Tech Solutions, Inc. and changed its name to Q BioMed Inc. in July 2015. Q BioMed Inc. was incorporated in 2013 and is based in New York, New York.

+212 5880022

366 Madison Avenue
New York, NY 10017

CIK: 0001596062
ISIN: US74736N1054
CUSIP: 74736N105